Posted inHematology-Oncology Wellness & Lifestyle
Enhancing Patient Experience in DLBCL: Insights from PROs and Clinician-Reported AEs in the Phase 3 POLARIX Trial
The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of life comprehensively.